Cite
Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
MLA
Rosenstock, Julio, et al. “Switching to IGlarLixi versus Continuation of a Daily or Weekly Glucagon‐like Peptide‐1 Receptor Agonist (GLP‐1 RA) in Insufficiently Controlled Type 2 Diabetes: A LixiLan‐G Trial Subgroup Analysis by HbA1c and GLP‐1 RA Use at Screening.” Diabetes, Obesity & Metabolism, vol. 23, no. 6, June 2021, pp. 1331–41. EBSCOhost, https://doi.org/10.1111/dom.14345.
APA
Rosenstock, J., Blonde, L., Aroda, V. R., Frias, J., Souhami, E., Ji, C., Niemoeller, E., & Del Prato, S. (2021). Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening. Diabetes, Obesity & Metabolism, 23(6), 1331–1341. https://doi.org/10.1111/dom.14345
Chicago
Rosenstock, Julio, Lawrence Blonde, Vanita R. Aroda, Juan Frias, Elisabeth Souhami, Chen Ji, Elisabeth Niemoeller, and Stefano Del Prato. 2021. “Switching to IGlarLixi versus Continuation of a Daily or Weekly Glucagon‐like Peptide‐1 Receptor Agonist (GLP‐1 RA) in Insufficiently Controlled Type 2 Diabetes: A LixiLan‐G Trial Subgroup Analysis by HbA1c and GLP‐1 RA Use at Screening.” Diabetes, Obesity & Metabolism 23 (6): 1331–41. doi:10.1111/dom.14345.